All In Biotech

Drug Trial Radar · NCT06837142

A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects

Last checked: Nov 19, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Mar 11, 2025

Primary completion

Apr 30, 2025

Study completion Apr 30, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 39 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An open-label, single-center, single-sequence study to evaluate the drug-drud interaction between the CYP3A substrate triazolam and TS-172 (part A) and the potent CYP3A inhibitor itraconazole and TS-172 (part B) in healthy male subjects on their pharmacokinetics, safety and tolerability

Conditions

  • Healthy Male Subjects

Interventions

  • Triazolam and TS-172Drug

    Oral single administration of triazolam 0.25 mg at single administration phase, followed by a oral single administration of triazolam 0.25 mg and TS-172 20 mg at concomitant administration phase

  • TS-172 and itraconazoleDrug

    Oral single administrtation of TS-172 20 mg at single administration phase, followed by a oral single administration of TS-172 and itoraconazole 200 mg at concomitant administration phase

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Maximum plasma concentration (Cmax) of unchanged form of triazolamTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours after dosing
  2. Part A: Area under the concentration-time curve (AUC) from time zero to time of the last quantifiable concentration of unchanged form of triazolam in plasmaTime frame: Up to 24 hours postdose
  3. Part A: Area under the concentration-time curve (AUC) from time zero extrapolated to infinite time of unchanged form of triazolam in plasmaTime frame: Up to 24 hours postdose
  4. Part B: Maximum plasma concentration (Cmax) of unchanged form of TS-172 and its metaboliteTime frame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours after dosing
  5. Part B: Area under the concentration-time curve (AUC) from time zero to time of the last quantifiable concentration of unchanged form of TS-172 and its metabolite in plasmaTime frame: Up to 48 hours postdose
  6. Part B: Area under the concentration-time curve (AUC) from time zero extrapolated to infinite time of unchanged form of TS-172 and its metabolite in plasmaTime frame: Up to 48 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taisho Pharmaceutical Co., Ltd selected site

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.